In a post hoc analysis of 135 patients with extremity soft-tissue sarcoma from EORTC 62961, adding regional hyperthermia to neoadjuvant chemotherapy gave a non-significant OS improvement (HR 0.67; p=.081); no significant interaction with Sarculator risk.
Secondary analysisn = 135
Albertsmeier et al. Neoadjuvant chemotherapy for soft-tissue sarcoma of the extremities: A post-hoc Sarculator-based risk analysis of the EORTC 62961-ESHO 95 randomized trial